Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma: Difference between revisions
Jump to navigation
Jump to search
wikispore>Pkdilena (Created page with "{{item |type_parameter=research |description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurre...") |
wikispore>Pkdilena No edit summary |
||
| Line 17: | Line 17: | ||
|con_nam=Eliza Hawkes | |con_nam=Eliza Hawkes | ||
|con_tas=Lead Chief Investigator | |con_tas=Lead Chief Investigator | ||
|con_cop= | |con_cop=paid | ||
|con_dates=No | |con_dates=No | ||
}} | }} | ||
| Line 23: | Line 23: | ||
|inp_typ=funding | |inp_typ=funding | ||
|inp_inp=1,225,487.40 | |inp_inp=1,225,487.40 | ||
|inp_currency=AUD | |||
}} | }} | ||
}} | }} | ||
Revision as of 05:36, 27 March 2023
Description: Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
Dates
State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-03-27
Report authors
Portia Dilena (link)
Location
Australia
Aims
maximise survival of these young Australians
Category
research
Inputs
individual
Eliza Hawkes
Task: Lead Chief Investigator
Compensation: paid
funding
1,225,487.40 (AUD)